Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer

Table 2

Treatment response in the group and in the group.

Response					value
		%		%
No. patients	81		56
Response
CR	2	2.5%	1	1.8%
PR	27	33.3%	15	26.8%
SD	41	50.6%	28	50.0%
PD	11	13.6%	12	21.4%
ORR					0.377
CR+PR	29	35.8%	16	28.6%
SD+PD	52	64.2%	40	71.4%
DCR					0.229
CR+PR+SD	70	86.4%	44	78.6%
PD	11	13.6%	12	21.4%